Agenturet vil fuldt ud tage højde for sit ansvar for at vurdere fire klasser af lægemidler, hvor der nu skal søges om godkendelse via den centraliserede procedure, nemlig hiv/ aids, cancer, diabetes og neurodegenerative sygdomme.
The Agency will fully embrace its responsibility to assess four classes of medicines for which authorisation must now be sought through the centralised procedure: those for HIV/ AIDS, cancer, diabetes and neurodegenerative disorder.